---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-23-005994"
form_type: "8-K"
ticker: "ZSQR"
cik: "0001759186"
company_name: "Z Squared Inc."
filed_at: "2023-08-22T23:59:59+00:00"
generated_at: "2026-06-11T05:39:29.295862+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Coeptis completes exclusive license of Deverra allogeneic NK cell platform and two Phase 1 assets

## Summary
- Paid ~$570K cash and issued 4M shares to Deverra for exclusive rights to allogeneic stem cell expansion platform.
- Acquired two IND applications and Phase 1 trials (NCT04901416, NCT04900454) for NK cell therapy DVX201.
- Platform generates off-the-shelf NK and myeloid cells; aligns with Coeptis' SNAP-CAR and GEAR technologies.
- Transaction moves Coeptis from pre-clinical to a clinical-stage company with two ongoing Phase 1 studies.
- Pipeline includes unmodified NK cells for AML/MDS and viral infections plus engineered NK/MAC candidates.

## SEC filing metadata
- accession: 0001683168-23-005994
- form_type: 8-K
- ticker: ZSQR
- cik: 0001759186
- company_name: Z Squared Inc.
- filed_at: 2023-08-22T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759186/000168316823005994/0001683168-23-005994-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759186/000168316823005994/coeptis_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-23-005994
- JSON: https://secwatch.observer/filing/0001683168-23-005994.json
- Plain text: https://secwatch.observer/filing/0001683168-23-005994.txt

## Key facts
- Material Agreements
  Z Squared Inc. entered into License Agreement with Deverra Therapeutics Inc. (effective 2023-08-16).
  - Action: entry
  - Agreement: license
  - Counterparty: Deverra Therapeutics Inc.
  - Effective: 2023-08-16
  source text: On August 16, 2023, Coeptis Therapeutics Holdings, Inc. (the “Company”) entered into an exclusive licensing arrangement (the “License Agreement”) with Deverra Therapeutics Inc. (“Deverra”), pursuant to which the Company completed the exclusive license of key patent families and related intellectual property related to a proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759186/000168316823005994/0001683168-23-005994-index.htm
- Material Agreements
  Z Squared Inc. entered into APA with Deverra Therapeutics Inc. valued at approximately $570,000 in cash (effective 2023-08-16).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Deverra Therapeutics Inc.
  - Value: approximately $570,000 in cash
  - Effective: 2023-08-16
  source text: In support of the exclusive license, the Company also entered into with Deverra (i) an asset purchase agreement (the “APA”) pursuant to which the Company purchased certain assets from Deverra, including but not limited to two Investigational New Drug (IND) applications and two Phase 1 clinical trial stage programs (NCT04901416, NCT04900454) investigating infusion of DVX201, an unmodified natural killer (NK) cell therapy generated from pooled donor CD34+ cells, in hematologic malignancies and viral infections
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759186/000168316823005994/0001683168-23-005994-index.htm
- Material Agreements
  Z Squared Inc. entered into Sublicense Agreement with Deverra Therapeutics Inc. (effective 2023-08-16).
  - Action: entry
  - Agreement: license
  - Counterparty: Deverra Therapeutics Inc.
  - Effective: 2023-08-16
  source text: a non-exclusive sublicense agreement (the “Sublicense Agreement”), in support of the assets obtained by the exclusive license, pursuant to which the Company sublicensed from Deverra certain assets which Deverra has rights to pursuant a license agreement (“FHCRC Agreement”) by and between Deverra and The Fred Hutchinson Cancer Research Center (“FHCRC”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759186/000168316823005994/0001683168-23-005994-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.